

AssayMax™ Human Factor V ELISA Kit

Assaypro LLC 3400 Harry S Truman Blvd St. Charles, MO 63301 T (636) 447-9175 F (636) 395-7419 www.assaypro.com

For any questions regarding troubleshooting or performing the assay, please contact our support team at support@assaypro.com.

Thank you for choosing Assaypro.

Assay Summary

Step 1. Add 50 μ l of Standard or Sample per well. Incubate 2 hours.

Step 2. Wash, then add 50 μ l of Biotinylated Antibody per well. Incubate 1 hour.

Step 3. Wash, then add 50 μ l of SP Conjugate per well. Incubate 30 minutes.

Step 4. Wash, then add 50 μ l of Chromogen Substrate per well. Incubate 30 minutes.

Step 5. Add 50 μ l of Stop Solution per well. Read at 450 nm immediately.

Symbol Key



Consult instructions for use.

Assay Template

12								
11								
10								
6								
80								
7								
9								
4								
8								
2								
1								
	٧	В	C	Q	E	Ŧ	ט	I

AssayMax™ Human Factor V (Factor 5) ELISA Kit

Catalog No. EF1005-1
Sample insert for reference use only

Introduction

Factor V (FV) is an essential cofactor of the blood coagulation cascade and circulates in plasma as a large single-chain glycoprotein (330 kDa). The deduced amino acid sequence consists of 2224 amino acids inclusive of a 28-amino acid leader peptide (1). During coagulation, it is converted to the active cofactor FVa via limited proteolysis by thrombin and is spliced into a heavy chain (110 kDa) and a light chain (73 kDa) held together non-covalently by calcium (2). In the presence of a calcium ion and the phospholipid on cell surfaces, FVa and FXa form the prothrombinase complex, which catalyzes the hydrolysis of prothrombin to thrombin (3). Then thrombin cleaves fibrinogen to fibrin, which polymerizes to form a clot. FVa is readily inactivated by anticoagulant activated protein C (4). FV Leiden, a single amino acid mutation, renders FVa resistant to cleavage by activated protein C. It, therefore, overproduces thrombin and leads to excess clotting and hereditary thrombophilia disorder (5). Severe FV deficiency is associated with mild to severe bleeding diathesis (6).

Principle of the Assay

The AssayMax™ Human Factor V ELISA (Enzyme-Linked Immunosorbent Assay) Kit is designed for detection of factor V in human plasma, milk, urine, and CSF samples. This assay employs a quantitative sandwich enzyme immunoassay technique that measures human factor V in approximately 4 hours. A polyclonal antibody specific for human factor V has been pre-coated onto a 96-well microplate with removable strips. Factor V in standards and samples is sandwiched by the immobilized antibody and a biotinylated polyclonal antibody specific for human factor V, which is recognized by a streptavidin-peroxidase (SP) conjugate. All unbound material is washed away and a peroxidase enzyme substrate is added. The color development is stopped and the intensity of the color is measured.

Caution and Warning

- This product is for Research Use Only and is not intended for use in diagnostic procedures.
- Prepare all reagents (diluent buffer, wash buffer, standard, biotinylated antibody, and SP conjugate), as instructed, prior to running the assay.

- Prepare all samples prior to running the assay. The dilution factors for the samples are suggested in this insert. However, the user should determine the optimal dilution factor.
- Spin down the SP conjugate vial and the biotinylated antibody vial before opening and using contents.
- The Stop Solution is an acidic solution.
- The kit should not be used beyond the expiration date.

Reagents

- Human Factor V Microplate: A 96-well polystyrene microplate (12 strips of 8 wells) coated with a polyclonal antibody against human factor V.
- Sealing Tapes: Each kit contains 3 precut, pressure sensitive sealing tapes that can be cut to fit the format of the individual assay.
- Human Factor V Standard: Human factor V in a buffered protein base, calibrated against WHO 2nd International Standard (13.5 ng, lyophilized, 2 vials).
- Biotinylated Human Factor V Antibody (50x): A 50-fold concentrated biotinylated polyclonal antibody against human factor V (120 µl).
- EIA Diluent Concentrate (10x): A 10-fold concentrated buffered protein base (30 ml).
- Wash Buffer Concentrate (20x): A 20-fold concentrated buffered surfactant (30 ml, 2 bottles).
- SP Conjugate (100x): A 100-fold concentrate (80 μl).
- Chromogen Substrate (1x): A stabilized peroxidase chromogen substrate tetramethylbenzidine (7 ml).
- Stop Solution (1x): A 0.5 N hydrochloric acid solution to stop the chromogen substrate reaction (11 ml).

Storage Condition

- Upon arrival, immediately store components of the kit at recommended temperatures up to the expiration date.
- Store Standard, SP Conjugate, and Biotinylated Antibody at -20°C.
- Store Microplate, Diluent Concentrate (10x), Wash Buffer, Stop Solution, and Chromogen Substrate at 2-8°C.
- Unused microplate wells may be returned to the foil pouch with the desiccant packs and resealed. May be stored for up to 30 days in a vacuum desiccator.

Other Supplies Required

- Microplate reader capable of measuring absorbance at 450 nm
- Pipettes (1-20 μl, 20-200 μl, 200-1000 μl, and multiple channel)

Deionized or distilled reagent grade water

Sample Collection, Preparation, and Storage

- Plasma: Collect plasma using one-tenth volume of 0.1 M sodium citrate as an anticoagulant. Centrifuge samples at 3000 x g for 10 minutes and collect plasma. A 4000-fold sample dilution is suggested into EIA Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles (EDTA or Heparin can also be used as an anticoagulant).
- Milk: Collect milk using sample tube. Centrifuge samples at 800 x g for 10 minutes. The sample is suggested for use at 1x or within the range of 2x 10x into EIA Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- Urine: Collect urine using sample pot. Centrifuge samples at 800 x g for 10 minutes. The sample is suggested for use at 1x or within the range of 2x 10x into EIA Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- CSF: Collect cerebrospinal fluid (CSF) using sample pot. Centrifuge samples at 3000 x g for 10 minutes. A 2-fold sample dilution is suggested into EIA Diluent or within the range of 1x 10x; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -80°C for up to 3 months. Avoid repeated freeze-thaw cycles.

Applicable samples may also include biofluids, cell culture, and tissue homogenates. If necessary, user should determine optimal dilution factor depending on application needs.

Refer to Dilution Guidelines for further instruction.

	Guidelines for Dilutions of 100-fold or Greater (for reference only; please follow the insert for specific dilution suggested)				
	100x		10000x		
A)	4 μl sample : 396 μl buffer (100x) = 100-fold dilution Assuming the needed volume is less than or equal to 400 μl.	A) B)	4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x) = 10000-fold dilution Assuming the needed volume is less than or equal to 400 μl.		
	1000x		100000x		
A) B)	4 μl sample : 396 μl buffer (100x) 24 μl of A : 216 μl buffer (10x) = 1000-fold dilution Assuming the needed volume is less than or equal to 240 μl.	A) B) C)	4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x) 24 μl of B : 216 μl buffer (10x) = 100000-fold dilution Assuming the needed volume is less than or equal to 240 μl.		

Reagent Preparation

- Freshly dilute all reagents and bring all reagents to room temperature before use.
- **EIA Diluent Concentrate (10x):** Dilute the EIA Diluent Concentrate 10-fold with reagent grade water to produce a 1x solution. When diluting the concentrate, make sure to rinse the bottle thoroughly to extract any precipitates left in the bottle. Mix the 1x solution gently until the crystals have completely dissolved. Store for up to 30 days at 2-8°C.
- Human Factor V Standard: Reconstitute the Human Factor V Standard (13.5 ng, 1.35 mIU) with 0.45 ml of EIA Diluent to generate a 30 ng/ml (3 mIU/ml) standard stock solution. Allow the vial to sit for 10 minutes with gentle agitation prior to making dilutions. Prepare duplicate or triplicate standard points by serially diluting from the standard stock solution (30 ng/ml) 4-fold with EIA Diluent to produce 7.5, 1.875, 0.469, and 0.117 ng/ml solutions. EIA Diluent serves as the zero standard (0 ng/ml). Aliquot remaining stock solution to limit repeated freeze-thaw cycles. This solution should be stored at -20°C and used within 5 days.

Standard Point	Dilution	[FV] (ng/ml)	[FV] (mIU/ml)
P1	1 part Standard (30 ng/ml)	30	3.0
P2	1 part P1 + 3 parts EIA Diluent	7.5	0.75
Р3	1 part P2 + 3 parts EIA Diluent	1.875	0.188
P4	1 part P3 + 3 parts EIA Diluent	0.469	0.047
P5	1 part P4 + 3 parts EIA Diluent	0.117	0.012
P6	EIA Diluent	0.0	0.0

- Biotinylated Human Factor V Antibody (50x): Spin down the antibody briefly and dilute the desired amount of the antibody 50-fold with EIA Diluent to produce a 1x solution. The undiluted antibody should be stored at -20°C.
- Wash Buffer Concentrate (20x): Dilute the Wash Buffer Concentrate 20fold with reagent grade water to produce a 1x solution. When diluting
 the concentrate, make sure to rinse the bottle thoroughly to extract any
 precipitates left in the bottle. Mix the 1x solution gently until the crystals
 have completely dissolved.
- SP Conjugate (100x): Spin down the SP Conjugate briefly and dilute the
 desired amount of the conjugate 100-fold with EIA Diluent to produce a
 1x solution. The undiluted conjugate should be stored at -20°C.

Assay Procedure

- Prepare all reagents, standard solutions, and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature (20-25°C).
- Remove excess microplate strips from the plate frame and return them immediately to the foil pouch with desiccants inside. Reseal the pouch securely to minimize exposure to water vapor and store in a vacuum desiccator.
- Add 50 µl of Human Factor V Standard or sample to each well. Gently tap
 plate to thoroughly coat the wells. Break any bubbles that may have
 formed. Cover wells with a sealing tape and incubate for 2 hours. Start
 the timer after the last addition.
- Wash the microplate manually or automatically using a microplate washer. Invert the plate and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If washing manually, wash five times with 200 μl of Wash Buffer per well. Invert the plate each time and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If using a microplate washer, wash six times with 300 μl of Wash Buffer per well; invert the plate and hit 4-5 times on absorbent material to completely remove the liquid.
- Add 50 µl of Biotinylated Human Factor V Antibody to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 1 hour.
- Wash the microplate as described above.
- Add 50 µl of SP Conjugate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 30 minutes. Turn on the microplate reader and set up the program in advance.
- Wash the microplate as described above.
- Add 50 µl of Chromogen Substrate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed.

- Incubate in ambient light for 30 minutes or until the optimal blue color density develops.
- Add 50 µl of Stop Solution to each well. The color will change from blue to yellow. Gently tap plate to ensure thorough mixing. Break any bubbles that may have formed.
- Read the absorbance on a microplate reader at a wavelength of 450 nm immediately. If wavelength correction is available, subtract readings at 570 nm from those at 450 nm to correct optical imperfections.
 Otherwise, read the plate at 450 nm only. Please note that some unstable black particles may be generated at high concentration points after stopping the reaction for about 10 minutes, which will reduce the readings.

Data Analysis

- Calculate the mean value of the duplicate or triplicate readings for each standard and sample.
- To generate a standard curve, plot the graph using the standard concentrations on the x-axis and the corresponding mean 450 nm absorbance (OD) on the y-axis. The best fit line can be determined by regression analysis using log-log or four-parameter logistic curve fit.
- Determine the unknown sample concentration from the Standard Curve and multiply the value by the dilution factor.

Typical Data

The typical data is provided for reference only. Individual laboratory
means may vary from the values listed. Variations between laboratories
may be caused by technique differences.

Standard Point	ng/ml	OD	Average OD	
P1	30	2.247	2.281	
PI	30	2.315	2.281	
P2	7.5	1.716	1.678	
r Z	7.5	1.640	1.078	
P3	1.875	0.777	0.804	
rs	1.673	0.831	0.804	
P4	0.469	0.311	0.323	
P4	0.409	0.335	0.525	
P5 0.117		0.128	0.133	
ro	0.117	0.138	0.133	
P6	0.0	0.064	0.061	
PU	0.0	0.058	0.001	
Sample: Poo	oled Normal	0.967	0.046	
Sodium Citrate	Plasma (4000x)	0.925	0.946	

Standard Curve

• The curve is provided for illustration only. A standard curve should be generated each time the assay is performed.

Performance Characteristics

- Kit standard has been calibrated against WHO International Standard.
- The minimum detectable dose of human factor V as calculated by 2SD from the mean of a zero standard was established to be 54 pg/ml.
- Intra-assay precision was determined by testing three plasma samples twenty times in one assay.
- Inter-assay precision was determined by testing three plasma samples in twenty assays.

	Intra-Assay Precision			Inter	-Assay Pred	ision
Sample	1	2	3	1	2	3
n	20	20	20	20	20	20
CV (%)	5.3%	5.0%	6.5%	10.4%	9.5%	11.0%
Average CV (%)	_	5.6%			10.3%	

Spiking Recovery

 Recovery was determined by spiking two plasma samples with different factor V concentrations.

Sample	Unspiked Sample (ng/ml)	Spiking Value (ng/ml)	Expected	Observed	Recovery (%)
1	3.139	1.244	4.383	4.749 3.752	108%
	3.139	0.278	3.417		110%
		3.726	4.819	4.345	90%
2	1.093	1.244	2.337	2.092	90%
		0.278	1.371	1.256	92%
Average Recovery (%)					98%

Linearity

Plasma samples were serially diluted to test for linearity.

Average Percentage of Expected Value (%)				
Sample Dilution	Plasma			
2000x	94%			
4000x	102%			
8000x	105%			

Cross-Reactivity

Species	Cross-Reactivity (%)
Canine	None
Monkey	5%
Mouse	None
Rat	None
Swine	<3%
Rabbit	None

 No significant cross-reactivity observed with human factor I (fibrinogen), factor II (prothrombin), factor III (tissue factor), factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, factor XIV (protein C), and VWF proteins.

Troubleshooting

Issue	Causes	Course of Action
	Use of improper components	Check the expiration date listed before use. Do not interchange components from different lots.
	Improper wash step	Check that the correct wash buffer is being used. Check that all wells are empty after aspiration. Check that the microplate washer is dispensing properly. If washing by pipette, check for proper pipetting technique.
cisior	Splashing of reagents while loading wells	Pipette properly in a controlled and careful manner.
Low Precision	Inconsistent volumes loaded into wells	Pipette properly in a controlled and careful manner. Check pipette calibration. Check pipette for proper performance.
د	Insufficient mixing of reagent dilutions	Thoroughly agitate the lyophilized components after reconstitution. Thoroughly mix dilutions.
	Improperly sealed microplate	 Check the microplate pouch for proper sealing. Check that the microplate pouch has no punctures. Check that three desiccants are inside the microplate pouch prior to sealing.
r or ity	Microplate was left unattended between steps	Each step of the procedure should be performed uninterrupted.
ow	Omission of step	 Consult the provided procedure for complete list of steps.
Unexpectedly Low or High Signal Intensity	Steps performed in incorrect order	Consult the provided procedure for the correct order.
cte	Insufficient amount of	Check pipette calibration.
pe Sig	reagents added to wells	Check pipette for proper performance.
ex gh	Wash step was skipped	Consult the provided procedure for all wash steps.
P ii	Improper wash buffer	Check that the correct wash buffer is being used. Consult reasons proposition section for the correct.
	Improper reagent preparation	 Consult reagent preparation section for the correct dilutions of all reagents.

	Insufficient or prolonged incubation periods	Consult the provided procedure for correct incubation time.
Deficient Standard Curve Fit	Non-optimal sample dilution	 Sandwich ELISA: If samples generate OD values higher than the highest standard point (P1), dilute samples further and repeat the assay. Competitive ELISA: If samples generate OD values lower than the highest standard point (P1), dilute samples further and repeat the assay. User should determine the optimal dilution factor for samples.
anda	Contamination of reagents	 A new tip must be used for each addition of different samples or reagents during the assay procedure.
nt Sta	Contents of wells evaporate	 Verify that the sealing film is firmly in place before placing the assay in the incubator or at room temperature.
Deficie	Improper pipetting	 Pipette properly in a controlled and careful manner. Check pipette calibration. Check pipette for proper performance.
	Insufficient mixing of reagent dilutions	 Thoroughly agitate the lyophilized components after reconstitution. Thoroughly mix dilutions.

References

- (1) Jenny RJ et al. (1987) Proc Natl Acad Sci USA. 84:4846-4850.
- (2) Esmon CT. (1979) J Biol Chem. 254:964-973.
- (3) Nesheim ME et al. (1981) J Biol Chem. 256:6537-6540.
- (4) Kisiel W et al. (1977) Biochemistry. 16:5824-5831.
- (5) Bertina RM et al. (1994) Nature. 369:64-67.
- (6) Asselta R et al. (2006) J Thromb Haemost. 4(1):26-34.

Version 2.6